التفاصيل البيبلوغرافية
| العنوان: |
Efficacy of Supra-HFR in Removing FGF23 and Cytokines: A Single Session Analysis. |
| المؤلفون: |
DONATI, GABRIELE, ANGELETTI, ANDREA, CAPPUCCILLI, MARIA, DONADEI, CHIARA, GUGLIELMO, CHIARA, SCRIVO, ANNA, GASPERONI, LORENZO, ZAMBELLI, MADDALENA, MATTIOTTI, MARIA, MANNA, GAETANO LA |
| المصدر: |
In Vivo; Jul/Aug2022, Vol. 36 Issue 4, p1769-1776, 8p |
| مصطلحات موضوعية: |
CYTOKINES, HEMODIAFILTRATION, MOLECULAR weights, FIBROBLAST growth factors, KIDNEY diseases |
| مستخلص: |
Background/Aim: Supra hemodiafiltration with reinfusion of the endogenous ultrafiltrate (Supra-HFR) is a dialysis technique used to improve uremic toxin removal in the range of the middle molecular weight molecules. Supra-HFR does not require the preparation and online infusion of highpurity dialysis water because it allows the production of an endogenous ultrafiltrate that undergoes detoxification through an adsorbing resin. Patients and Methods: We investigated the ability of Supra-HFR to remove fibroblast growth factor 23 (FGF23), interleukin 6 (IL-6), tumor necrosis factor alpha (TNFalpha), interleukin 8 (IL-8), and transforming growth factor alpha (TGF-alpha) after a single session dialysis in nine patients affected by end stage renal disease (ESRD). The same patients underwent a single session of online hemodiafiltration (OLHDF) to evaluate possible differences in FGF23 and IL-6 levels. Results: A significant reduction in FGF23 was observed with both Supra-HFR (p=0.001) and OL-HDF. As for TNF-alpha and TGF-alpha, which were measured using Supra-HFR only, their percentage values were significantly lower at the end of dialysis than at the start (p=0.0028 and p=0.03, respectively). This did not change with post-dialysis rebound. Supra-HFR was found to have no effect on IL-6 and IL-8. Interestingly, the removal rate for FGF23 and IL-6 was similar to that observed with OL-HDF. Conclusion: Supra-HFR was not superior to OL-HDF, with suboptimal convective volume in the removal of the molecules tested, especially FGF23, which is considered a large middle molecular weight uremic toxin. [ABSTRACT FROM AUTHOR] |
|
Copyright of In Vivo is the property of International Institute of Anticancer Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
